MedTrace Logo

Effect of Pioglitazone vs Metformin on Clinical, Biochemical and Hormonal Parameters of Insulin Resistant PCOS

NCT07472179 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-16

No results posted yet for this study

Summary

Women with PCOS with HOMA-IR \>2 fulfilling inclusion and exclusion criteria are randomly allocated into two groups: group A: pioglitazone 30 mg once daily and group B: Metformin 500 thrice daily for 3 months.Each group contains 30 participants. Outcome variables are measured after 3 months.

Conditions

  • PCOS(Insulin Resistant)

Interventions

DRUG

Pioglitazone 30 Mg Oral Tablet

pioglitazone 30 mg once daily for 3 months

DRUG

metformin 500 mg thrice daily

tab. Metformin 500 mg given 3 times daily for 3 months

Sponsors & Collaborators

  • Bangladesh Medical University

    collaborator OTHER

  • Mst.Sumyara Khatun

    lead OTHER

Principal Investigators

  • Farzana Deeba, MBBS,FCPS,MS,MRCOG · Bangladesh Medical University

  • Ismat Jahan Kumkum, MBBS · Bangladesh Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-12
Primary Completion
2025-12-12
Completion
2026-02-20

Countries

  • Bangladesh

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07472179 on ClinicalTrials.gov